ENHABIT INC (EHAB) Stock Fundamental Analysis
NYSE:EHAB - New York Stock Exchange, Inc. - US29332G1022 - Common Stock - Currency: USD
Taking everything into account, EHAB scores 2 out of 10 in our fundamental rating. EHAB was compared to 105 industry peers in the Health Care Providers & Services industry. EHAB has a bad profitability rating. Also its financial health evaluation is rather negative. EHAB has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
EHAB had positive earnings in the past year.
EHAB had a positive operating cash flow in the past year.
In multiple years EHAB reported negative net income over the last 5 years.
EHAB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
EHAB's Return On Assets of -12.74% is on the low side compared to the rest of the industry. EHAB is outperformed by 77.14% of its industry peers.
Looking at the Return On Equity, with a value of -29.84%, EHAB is doing worse than 67.62% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 3.35%, EHAB is in line with its industry, outperforming 47.62% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for EHAB is significantly below the industry average of 8.81%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.74% | ||
| ROE | -29.84% | ||
| ROIC | 3.35% |
ROA(3y)-7%
ROA(5y)-1.92%
ROE(3y)-15.77%
ROE(5y)-6.79%
ROIC(3y)3.74%
ROIC(5y)4.76%
1.3 Margins
Looking at the Operating Margin, with a value of 4.50%, EHAB is in line with its industry, outperforming 57.14% of the companies in the same industry.
In the last couple of years the Operating Margin of EHAB has declined.
The Gross Margin of EHAB (48.71%) is better than 76.19% of its industry peers.
In the last couple of years the Gross Margin of EHAB has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.5% | ||
| PM (TTM) | N/A | ||
| GM | 48.71% |
OM growth 3Y-29.61%
OM growth 5Y-4.28%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.12%
GM growth 5Y-1.19%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), EHAB is destroying value.
Compared to 1 year ago, EHAB has more shares outstanding
EHAB has a worse debt/assets ratio than last year.
2.2 Solvency
EHAB has an Altman-Z score of 1.48. This is a bad value and indicates that EHAB is not financially healthy and even has some risk of bankruptcy.
EHAB's Altman-Z score of 1.48 is on the low side compared to the rest of the industry. EHAB is outperformed by 61.90% of its industry peers.
EHAB has a debt to FCF ratio of 10.87. This is a negative value and a sign of low solvency as EHAB would need 10.87 years to pay back of all of its debts.
EHAB has a Debt to FCF ratio (10.87) which is in line with its industry peers.
A Debt/Equity ratio of 0.94 indicates that EHAB is somewhat dependend on debt financing.
EHAB has a worse Debt to Equity ratio (0.94) than 63.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.94 | ||
| Debt/FCF | 10.87 | ||
| Altman-Z | 1.48 |
ROIC/WACC0.38
WACC8.73%
2.3 Liquidity
A Current Ratio of 1.53 indicates that EHAB should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.53, EHAB is in line with its industry, outperforming 56.19% of the companies in the same industry.
EHAB has a Quick Ratio of 1.53. This is a normal value and indicates that EHAB is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.53, EHAB is in line with its industry, outperforming 59.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.53 | ||
| Quick Ratio | 1.53 |
3. Growth
3.1 Past
The earnings per share for EHAB have decreased by -4.55% in the last year.
EHAB shows a decrease in Revenue. In the last year, the revenue decreased by -1.10%.
Measured over the past years, EHAB shows a decrease in Revenue. The Revenue has been decreasing by -1.07% on average per year.
EPS 1Y (TTM)-4.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
Revenue 1Y (TTM)-1.1%
Revenue growth 3Y-2.21%
Revenue growth 5Y-1.07%
Sales Q2Q%-0.92%
3.2 Future
Based on estimates for the next years, EHAB will show a decrease in Earnings Per Share. The EPS will decrease by -6.14% on average per year.
Based on estimates for the next years, EHAB will show a small growth in Revenue. The Revenue will grow by 5.98% on average per year.
EPS Next Y85.38%
EPS Next 2Y48.12%
EPS Next 3Y32.6%
EPS Next 5Y-6.14%
Revenue Next Year3.22%
Revenue Next 2Y4.04%
Revenue Next 3Y4.09%
Revenue Next 5Y5.98%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 37.05, EHAB can be considered very expensive at the moment.
The rest of the industry has a similar Price/Earnings ratio as EHAB.
EHAB's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 28.79.
The Price/Forward Earnings ratio is 19.98, which indicates a rather expensive current valuation of EHAB.
Based on the Price/Forward Earnings ratio, EHAB is valued a bit cheaper than the industry average as 64.76% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of EHAB to the average of the S&P500 Index (21.38), we can say EHAB is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.05 | ||
| Fwd PE | 19.98 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, EHAB is valued a bit cheaper than 66.67% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, EHAB is valued cheaper than 88.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.29 | ||
| EV/EBITDA | 11.26 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as EHAB's earnings are expected to grow with 32.60% in the coming years.
PEG (NY)0.43
PEG (5Y)N/A
EPS Next 2Y48.12%
EPS Next 3Y32.6%
5. Dividend
5.1 Amount
EHAB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.78
+0.08 (+1.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners101.3%
Inst Owner ChangeN/A
Ins Owners2.71%
Ins Owner Change16.38%
Market Cap392.73M
Analysts75
Price Target9.18 (17.99%)
Short Float %3.22%
Short Ratio4.61
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-25.32%
Min EPS beat(2)-28.32%
Max EPS beat(2)-22.31%
EPS beat(4)2
Avg EPS beat(4)10.15%
Min EPS beat(4)-28.32%
Max EPS beat(4)62.97%
EPS beat(8)3
Avg EPS beat(8)-0.05%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-3.64%
Min Revenue beat(2)-4.98%
Max Revenue beat(2)-2.3%
Revenue beat(4)0
Avg Revenue beat(4)-3.92%
Min Revenue beat(4)-4.98%
Max Revenue beat(4)-2.3%
Revenue beat(8)0
Avg Revenue beat(8)-4.03%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.12%
PT rev (3m)1.12%
EPS NQ rev (1m)2.4%
EPS NQ rev (3m)4.58%
EPS NY rev (1m)0%
EPS NY rev (3m)33.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.04%
Revenue NY rev (1m)-0.37%
Revenue NY rev (3m)-0.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.05 | ||
| Fwd PE | 19.98 | ||
| P/S | 0.38 | ||
| P/FCF | 8.29 | ||
| P/OCF | 7.67 | ||
| P/B | 0.75 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.26 |
EPS(TTM)0.21
EY2.7%
EPS(NY)0.39
Fwd EY5%
FCF(TTM)0.94
FCFY12.07%
OCF(TTM)1.01
OCFY13.04%
SpS20.5
BVpS10.37
TBVpS-8.61
PEG (NY)0.43
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.74% | ||
| ROE | -29.84% | ||
| ROCE | 4.24% | ||
| ROIC | 3.35% | ||
| ROICexc | 3.44% | ||
| ROICexgc | 32.49% | ||
| OM | 4.5% | ||
| PM (TTM) | N/A | ||
| GM | 48.71% | ||
| FCFM | 4.58% |
ROA(3y)-7%
ROA(5y)-1.92%
ROE(3y)-15.77%
ROE(5y)-6.79%
ROIC(3y)3.74%
ROIC(5y)4.76%
ROICexc(3y)3.81%
ROICexc(5y)4.84%
ROICexgc(3y)39.56%
ROICexgc(5y)58.49%
ROCE(3y)4.73%
ROCE(5y)6.02%
ROICexcg growth 3Y-27.94%
ROICexcg growth 5YN/A
ROICexc growth 3Y-21.68%
ROICexc growth 5YN/A
OM growth 3Y-29.61%
OM growth 5Y-4.28%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.12%
GM growth 5Y-1.19%
F-Score4
Asset Turnover0.84
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.94 | ||
| Debt/FCF | 10.87 | ||
| Debt/EBITDA | 6.31 | ||
| Cap/Depr | 12.06% | ||
| Cap/Sales | 0.37% | ||
| Interest Coverage | 1.09 | ||
| Cash Conversion | 65.56% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.53 | ||
| Quick Ratio | 1.53 | ||
| Altman-Z | 1.48 |
F-Score4
WACC8.73%
ROIC/WACC0.38
Cap/Depr(3y)51.64%
Cap/Depr(5y)35.82%
Cap/Sales(3y)1.58%
Cap/Sales(5y)1.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
EPS Next Y85.38%
EPS Next 2Y48.12%
EPS Next 3Y32.6%
EPS Next 5Y-6.14%
Revenue 1Y (TTM)-1.1%
Revenue growth 3Y-2.21%
Revenue growth 5Y-1.07%
Sales Q2Q%-0.92%
Revenue Next Year3.22%
Revenue Next 2Y4.04%
Revenue Next 3Y4.09%
Revenue Next 5Y5.98%
EBIT growth 1Y21.99%
EBIT growth 3Y-31.17%
EBIT growth 5Y-5.31%
EBIT Next Year76.35%
EBIT Next 3Y24.69%
EBIT Next 5YN/A
FCF growth 1Y5.57%
FCF growth 3Y-26.15%
FCF growth 5Y0%
OCF growth 1Y5.79%
OCF growth 3Y-25.39%
OCF growth 5Y-2.96%